Functional Dyspepsia
Conditions
Interventions
Probiotic Goat Milk Group:50g of Probiotic Goat Milk powder was mixed into 300ml solution for the subjects to drink for 60 days
Regular Goat Milk Group:50g of regular Goat Milk powder was mixed into 300ml solution for the subjects to drink for 60 days
Regular Cow Milk Group (RC MG):50 g of regular cow milk powder is diluted with warm water into a 300 mL solution for subjects to consume, with an intervention period of 60 consecutive days.
Sponsors
West China Fourth Hospital & West China School of Public Health, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 60 years; 2. Body mass index (BMI): 18.5 <= BMI <= 27.9; 3. Patients diagnosed with functional dyspepsia (FD) according to the Rome IV diagnostic criteria, with no organic lesions detected by gastroscopy within one year; 4. Permanent residence: Chengdu; 5.Willing to comply with the follow-up plan of this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients suffering from acute diarrhea, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS),inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), constipation, or celiac disease; 2. Patients with severe systemic diseases (such as cardiovascular, hepatic, renal, or hematological diseases); 3.Patients with confirmed Helicobacter pylori positivity diagnosed by the C13 urea breath test; 4. Patients who have used immunosuppressants or antibiotics within the past 1 month, or received pharmacotherapy related to functional dyspepsia within 2 weeks prior to the start of the study; 5.Probiotic exposure history: intake of probiotic-containing foods >=3 times per week within 3 months before screening; 6.Patients diagnosed with diabetes mellitus; 7.Patients with lactose intolerance or dairy product allergy; 8. Pregnant or lactating women; 9.Patients with cognitive or mental disorders who are unable to cooperate with examinations; 10. Participation in other similar clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrointestinal Symptom Rating Scale;Quality of Life Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein;IL-6;Gastrin-17;PG-?,PG-?;Composition structure, abundance changes and diversity characteristics of gut microbiota;Untargeted fecal metabolites; | — |
Countries
China
Contacts
Public ContactLi Ming
West China School of Public Health, Sichuan University
Outcome results
None listed